These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11055154)

  • 21. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 22. SEC slaps another researcher for insider trading. Securities and Exchange Commission.
    Skolnick AA
    JAMA; 1998 Jul; 280(2):124. PubMed ID: 9669773
    [No Abstract]   [Full Text] [Related]  

  • 23. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
    Leary TB
    J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical pricing. Let the market decide who gets discounts.
    Mossinghoff GJ
    Health Syst Rev; 1995; 28(1):24-5. PubMed ID: 10139754
    [No Abstract]   [Full Text] [Related]  

  • 25. In search of a breakthrough. Small medical devicemakers contend it's tough to crack the group purchasing domain; GPOs say they're open to true innovation.
    Becker C
    Mod Healthc; 2002 Aug; 32(31):28-32. PubMed ID: 12224360
    [No Abstract]   [Full Text] [Related]  

  • 26. Obstacles and opportunities in new drug development.
    Kaitin KI
    Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacies take uniform price demands to court.
    Moskowitz DB
    J Am Health Policy; 1994; 4(4):24-7. PubMed ID: 10136676
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug distribution dynamo. Cardinal Health, Bergen Brunswig propose mega-merger.
    Hensley S
    Mod Healthc; 1997 Sep; 27(35):20. PubMed ID: 10173141
    [No Abstract]   [Full Text] [Related]  

  • 29. Antitrust, health care quality, and the courts.
    Hammer PJ; Sage WM
    Columbia Law Rev; 2002 Apr; 102(3):545-649. PubMed ID: 11985363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do physicians need relief from antitrust laws?
    Trombetta W
    Mark Health Serv; 1997; 17(2):45-9. PubMed ID: 10170288
    [No Abstract]   [Full Text] [Related]  

  • 31. Developing a paradigm of drug innovation: an evaluation algorithm.
    Caprino L; Russo P
    Drug Discov Today; 2006 Nov; 11(21-22):999-1006. PubMed ID: 17055409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health care alliances--good medicine for an ailing health care industry, or antitrust illnesses to fence in?
    Sander NL
    Spec Law Dig Health Care Law; 1997 Dec; (226):9-49. PubMed ID: 10175045
    [No Abstract]   [Full Text] [Related]  

  • 33. Surveying the competition. FTC, DOJ report: competing benefits consumers.
    Taylor M
    Mod Healthc; 2004 Jul; 34(30):12. PubMed ID: 15301057
    [No Abstract]   [Full Text] [Related]  

  • 34. Antitrust exemption: are health providers crying wolf?
    Barnett AA
    J Am Health Policy; 1993; 3(3):38-41. PubMed ID: 10125734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Playing monopoly? FTC probes mammoth drug distributor merger.
    Becker C
    Mod Healthc; 2001 May; 31(20):34. PubMed ID: 11386133
    [No Abstract]   [Full Text] [Related]  

  • 36. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB
    Food Drug Law J; 1999; 54(2):185-6. PubMed ID: 11759712
    [No Abstract]   [Full Text] [Related]  

  • 37. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovation and compliance are not diametrically opposed.
    Raab GK
    Qual Assur; 1994 Mar; 3(1):2-8. PubMed ID: 7804614
    [No Abstract]   [Full Text] [Related]  

  • 39. Will we like tomorrow's giants?
    Scott L
    Mod Healthc; 1996 Aug; 26(32):79-80, 84-6, 88. PubMed ID: 10158987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing consolidation in healthcare markets: what are the antitrust policy implications?
    Haas-Wilson D; Gaynor M
    Health Serv Res; 1998 Dec; 33(5 Pt 2):1403-19. PubMed ID: 9865226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.